-
Notifications
You must be signed in to change notification settings - Fork 97
New issue
Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.
By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.
Already on GitHub? Sign in to your account
Potential XBB.1.9.1/(1.9.2 or XBB.1.22.2) recombinant (103 samples) with a branch with S:Y200C and S:K478R (16 samples) #2019
Comments
EPI_ISL_17257300 |
Thx @JosetteSchoenma ! To track the smaller sublineage of this one with S:K478R i suggest this query :A22161G,C15390A, T26457C, G12907A. cc @corneliusroemer @InfrPopGen @AngieHinrichs @thomaspeacock |
A27507C is also in AY.25 and XBB.1.22.2. |
Indeed, @aviczhl2 . I checked and it might have recombined with XBB.1.22.2 as well. It is the same from G15451A (ORF:G662S) and forward. XBB.1.22.2 does have C15237T, which this recombinant and XBB.1.9.1/2 do not have. So, the breakpoint would be after that in case it recombined with XBB.1.22.2. I do see 5 XBB.1.9.2 with C28770T, while I see no XBB.1.22.2 with it, which might make it sightly more likely that it recombined with XBB.1.9.2. The Delta's with A27507C look very different, of course. Thank you! I will adjust title. |
Sorry, what I actually want to express is that A27507C, despite being a synonym mutation, is moderately convergent, so it is more likely convergent mutation. But, yes, recombination is also very common in SARS-2 too, with so many variants and infection rate being so high. |
18 new samples. Mostly from South Korea, but also 3 from Shanghai and 2 from Australia. 74 in total now. |
96 samples now. New samples mostly from South Korea but one from Austria from the A28113G branch. |
@corneliusroemer ping |
103 samples now. New ones from South Korea, Indonesia and China (Anhui). |
After this analysis by @ryhisner showing this lineage has a heavy mutated orf3a, i suggest to designate this one to track it in the next weeks beyond any growth advantage talk |
135 samples as today . one new sample comes from Taiwan too. |
I designated the 200C/478R sublineage as FL.18.1.1 - yes it could potentially be an FY.5 recombinant, but too little evidence to sacrifice the benefit of hierarchical lineage names. |
Description: XBB.1.9.1/XBB.1.9.2 recombinant, with a big (mostly South Korean) branch with ORF8:I74V and a smaller branch which first gained S:Y200C and an ORF3a frameshift and after that a small saltation with S:478R (Australia, USA, the Netherlands, China)
Private mutations: C6285T, G12907A, C28770T
Breakpoint: between nucleotide 16878 and 27507
Earliest sequence: 2023-03-10 from England (with S:Y200C and ORF3a frameshift)
2023-03-22 from South Korea (with ORF8:I74V)
2023-03-29 from NSW/Australia (with extra small saltation with S:478R)
Most recent sequence: 2023-05-15 from Fujian/China
Countries circulating: South Korea 31, Australia/USA 7, China 3, Japan/England 2, the Netherlands/Indonesia/Ireland/Taiwan 1
GISAID query: C6285T, C11956T, A27507C
CovSpectrum query: https://cov-spectrum.org/explore/World/AllSamples/Past2M/variants?nucMutations=C6285T%2CC11956T%2CA27507C&nextcladePangoLineage1=xbb.1.9.1*&
to which S:T478R or A28113G could be added to find the various sublineages.
Usher tree:
https://nextstrain.org/fetch/genome.ucsc.edu/trash/ct/subtreeAuspice1_genome_8b73_effb30.json?branchLabel=nuc%20mutations&label=id:node_6674447
Please note that because the XBB.1.9.2. part only differs one mutation from XBB.1.9.1 (A27507C), convergent evolution cannot be ruled out. But because of the extra private mutations, I think recombination is more likely.
Please see this issue from Fede for more background info and discussion: sars-cov-2-variants/lineage-proposals#73.
The text was updated successfully, but these errors were encountered: